Mode
Text Size
Log in / Sign up
N/A N=162 Randomized Single-blind Treatment

Diabetes Journey: An Adolescent Adherence Barriers Intervention

Type 1 Diabetes · Adherence, Patient

Enrolled (actual)
162
Serious AEs
0.6%
Results posted
Jul 2025
Primary outcome: Primary: Barriers to Diabetes Adherence Questionnaire-Youth Report Stress/Burnout Subscale — 2.36; 2.31 score on a scale

Study Design & Population

Study type
Interventional
Phase
N/A
Interventions
Diabetes Journey (Behavioral); Enhanced Standard of Care (Behavioral)
Age
Pediatric · 13+ yrs
Sex
All
Sponsor
Children's Hospital Medical Center, Cincinnati
Primary completion
Mar 2024

Outcome Measures

OutcomeResultp-value
PRIMARY
Barriers to Diabetes Adherence Questionnaire-Youth Report Stress/Burnout Subscale
2.36; 2.31
PRIMARY
Barriers to Diabetes Adherence Questionnaire - Youth Report Time Pressure/Planning Subscale
1.92; 2.03
SECONDARY
Hemoglobin A1C
8.06; 7.98
SECONDARY
Type 1 Diabetes and Life -Youth Report
65.84; 65.82
SECONDARY
Adherence for Continuous Glucose Monitors
SECONDARY
Adherence
SECONDARY
Adherence for Insulin Pump Users
SECONDARY
Adherence to Insulin Boluses

Summary

The purpose of this study is to examine the feasibility, acceptability, and preliminary efficacy of a web-based intervention addressing adherence barriers in adolescents with T1D.

Eligibility Criteria

Inclusion Criteria

  • T1D diagnosis >1 year
  • Adolescents with T1D ages 13-17
  • Elevations on the Barriers to Diabetes Adherence questionnaire (scores of ≥3 of 53 for the Stress/Burnout and/or Time Pressure/Planning subscales) based on their previous clinic visit scores
  • Ability to read/speak English (all measures are in English)

Exclusion Criteria

  • Diagnosis of significant developmental disorders (e.g., autism spectrum disorder, moderate/severe developmental or intellectual disability)
  • Comorbid medical diagnoses (e.g., cystic fibrosis, asthma) with the exception of endocrine disorders (e.g., Celiac disease, thyroid)
  • No use of/plans to use non-insulin medication for blood glucose control
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT04404556). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search